=Epizyme (EPZM) reported positive study results from a key ongoing Phase 2 study

The Cambridge, Mass.-based firm unveiled what it cast as positive interim efficacy data from its ongoing Phase 2 study of tazemetostat as a single-agent treatment for relapsed or refractory patients that have follicular lymphoma or diffuse large B-cell lymphoma grouped by EZH2 mutational status. The data were presented at the International Conference on Malignant Lymphoma in in Lugano, Switzerland.

Data from a 62-gene panel biomarker study of tazemetostat in patients with various subtypes of non-Hodgkin lymphoma will also be presented at the conference.

"These Phase 2 interim data continue to confirm the activity of tazemetostat in patients with R/R DLBCL and FL and EZH2 mutations," wrote Leerink Partners LLC'sGeoffrey C. Porges in a note Wednesday morning. "Our initial take on the data are positive."